Your RSA-2048 keys break in 2030. Find every one of them before attackers do.
🛡️
Not in CISA KEV
HIGH severity

CVE-2026-66875

HIGH

CVE-2026-66875 is a high-severity (CVSS 8.8) Missing Authentication vulnerability. O3 Security confirms whether CVE-2026-66875 is actually reachable in your code before you act, and blocks exploitation at runtime until you patch.

In the Mira hormone monitor device firmware v1.7.1.47 build 01070147, a remote unauthenticated attacker within BLE range (approximately 10–30 meters) can silently rebind the device…

Published
Aug 11, 2026
Updated
Aug 11, 2026
Affected
0 pkgs
Patched
None yet
Exploits
None indexed
Exploitation data as of Aug 11, 2026 · OSV.dev, NVD, FIRST.org (EPSS)

Description

In the Mira hormone monitor device firmware v1.7.1.47 build 01070147, a remote unauthenticated attacker within BLE range (approximately 10–30 meters) can silently rebind the device to an attacker-controlled account, extract stored hormone measurements in cleartext, cause a denial-of-service via malformed or undocumented command opcodes, and passively track the user via a static random BLE address that never rotates.

Detection & mitigation playbook

Vulnerability
  1. Detect

    Scan your dependency tree (package-lock.json, pnpm-lock.yaml, requirements.txt, go.sum, etc.) for the affected component. O3's reachability analysis confirms whether the vulnerable code path is actually invoked in your application, so you act on real exposure instead of every transitive match.

  2. Remediation status

    No patched version of the affected component has shipped for CVE-2026-66875 yet. Where your build allows, override or pin the dependency away from the vulnerable range, and apply any maintainer-recommended mitigation.

  3. Mitigate without a patch

    If you can't upgrade right away: gate or disable the affected feature, validate untrusted input at the boundary, and avoid passing attacker-controlled data into the vulnerable path. O3's runtime protection blocks exploitation in production as an interim safeguard until the upgrade lands.

  4. How O3 protects you

    O3 pinpoints whether CVE-2026-66875 is reachable in your code and exactly where to fix it, then blocks exploitation in production at runtime until the patched version is deployed.

Tailored to CVE-2026-66875. Runtime protection reduces exposure until a permanent patch is applied and verified — it complements patching, it doesn't replace it.

Frequently Asked Questions

In the Mira hormone monitor device firmware v1.7.1.47 build 01070147, a remote unauthenticated attacker within BLE range (approximately 10–30 meters) can silently rebind the device to an attacker-controlled account, extract stored hormone measurements in cleartext, cause a denial-of-service via malformed or undocumented command opcodes, and passively track the user via a static random BLE address that never rotates.
O3 Security · Impact-Aware SCA

Is CVE-2026-66875 in your dependencies?

O3 detects CVE-2026-66875 across dependencies and uses function-level reachability to confirm whether the vulnerable code path is actually reachable — not just present. No false positives.